MDLinxCould This Cheap and Accessible Vitamin Outperform Current Alzheimer’s Treatments?

Read the original article

Clinical research examining benfotiamine, a form of vitamin B1, shows promise for early-stage Alzheimer’s disease treatment. A phase 2a trial demonstrated the supplement’s ability to improve synaptic activity and reduce advanced glycation end products while maintaining safety at doses that exceed normal thiamine blood levels.

Key Points:

• Benfotiamine effectively raises blood thiamine to therapeutic levels in patients with mild cognitive impairment, showing positive effects on synaptic function and AGE reduction
• The ongoing BenfoTeam clinical trial spans 40+ sites nationwide, testing benfotiamine’s effects in adults over 50 with early-stage Alzheimer’s
• Current FDA-approved Alzheimer’s medications face efficacy limitations and safety concerns, highlighting the need for alternative treatments
• Natural thiamine sources include whole grains, vegetables (potatoes, cauliflower, kale), fruits (oranges), and proteins (eggs, nuts)
• Additional brain health supplements studied include omega-3s, B6, B12, L-theanine, and acetyl L-carnitine
• Healthcare providers must evaluate drug-nutrient interactions when recommending supplements

“The ease of accessibility and lower cost of the benfotiamine for those with financial barriers is wonderful and provides a glimpse of hope for so many individuals who cannot easily obtain or afford the medications that they need to help optimize their quality of life.”
– Lena Bakovic, RDN

More on Alzheimer’s/Dementia